Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Agios Pharmaceuticals Inc. (AGIO-Q) is a biopharmaceutical company dedicated to advancing treatments for various cancers and rare diseases, notably focusing on anemia blood disorders. The company has made a significant step forward by selling a royalty for one of its drugs, which has considerably boosted its cash reserves. Analysts are optimistic about AGIO's performance, noting its attractive trading metrics, including a price-to-earnings ratio of 3x and a book value ratio of 1.2x, alongside a remarkable return on equity of 53%. The stock is recommended with a stop-loss set at $21, aiming for a target price of $43, which implies a potential upside of 28%. Despite not offering dividends, analysts have a price target of $57.00 for AGIO, indicating further confidence in its future prospects.

Consensus
Positive
Valuation
Undervalued
Similar
CLVS
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

We reiterate AGIO as a TOP PICK.  The developer of cancer treatment drugs expects two more products to go commercial over the next year- each with the potential to grow cash flows substantially.  It trades at 3x earnings, 1.2x book and supports and supports a robust 57% ROE.  We recommend trailing up the stop (from $21) to $25, looking to achieve $41 — upside potential of 28%.  Yield 0%

(Analysts’ price target is $54.57)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

AGIO is a biopharma company focusing on various cancer treatments.  It continues to advance its pipeline of new rare disease treatments include one for anemia blood disorder.  It has recently sold a royalty for one of its drugs that is increasing cash reserves dramatically.  We like that it trades at 3x earnings, 1.2x book and supports a ROE of 53%.  We recommend setting a stop-loss at $21, looking to achieve $43 -- upside potential of 28%.  Yield 0%

(Analysts’ price target is $57.00)
Showing 1 to 2 of 2 entries
  • «
  • 1
  • »

Agios Pharmaceuticals Inc.(AGIO-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Agios Pharmaceuticals Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Agios Pharmaceuticals Inc.(AGIO-Q) Frequently Asked Questions

What is Agios Pharmaceuticals Inc. stock symbol?

Agios Pharmaceuticals Inc. is a American stock, trading under the symbol AGIO-Q on the NASDAQ (AGIO). It is usually referred to as NASDAQ:AGIO or AGIO-Q

Is Agios Pharmaceuticals Inc. a buy or a sell?

In the last year, there was no coverage of Agios Pharmaceuticals Inc. published on Stockchase.

Is Agios Pharmaceuticals Inc. a good investment or a top pick?

Agios Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Agios Pharmaceuticals Inc..

Why is Agios Pharmaceuticals Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Agios Pharmaceuticals Inc. worth watching?

0 stock analysts on Stockchase covered Agios Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.

What is Agios Pharmaceuticals Inc. stock price?

On 2025-03-18, Agios Pharmaceuticals Inc. (AGIO-Q) stock closed at a price of $31.2.